Directive 2009/9 - Amendment of Directive 2001/82/EC on the EC code relating to medicinal products for veterinary use - Main contents
Please note
This page contains a limited version of this dossier in the EU Monitor.
Contents
official title
Commission Directive 2009/9/EC of 10 February 2009 amending Directive 2001/82/EC of the European Parliament and of the Council on the Community code relating to medicinal products for veterinary use| Legal instrument | Directive |
|---|---|
| Number legal act | Directive 2009/9 |
| CELEX number i | 32009L0009 |
| Document | 10-02-2009 |
|---|---|
| Publication in Official Journal | 14-02-2009; Special edition in Croatian: Chapter 13 Volume 029,OJ L 44, 14.2.2009 |
| Effect | 06-03-2009; Entry into force Date pub. + 20 See Art 3 |
| End of validity | 27-01-2022; Implicitly repealed by 32019R0006 |
| Transposition | 06-09-2009; At the latest See Art 2 |
14.2.2009 |
EN |
Official Journal of the European Union |
L 44/10 |
COMMISSION DIRECTIVE 2009/9/EC
of 10 February 2009
amending Directive 2001/82/EC of the European Parliament and of the Council on the Community code relating to medicinal products for veterinary use
(Text with EEA relevance)
THE COMMISSION OF THE EUROPEAN COMMUNITIES,
Having regard to the Treaty establishing the European Community,
Having regard to Directive 2001/82/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to veterinary medicinal products (1), and in particular Article 88 thereof,
Whereas:
(1) |
In order to be placed on the European Community market, a veterinary medicinal product must be granted a marketing authorisation by a competent authority. For this purpose, an application dossier containing particulars and documents relating to the results of tests and trials carried out on the veterinary medicinal product must be submitted. |
(2) |
The purpose of Annex I to Directive 2001/82/EC is to lay down detailed scientific and technical requirements regarding the testing of veterinary medicinal products against which the quality, safety and efficacy of the veterinary medicinal product should be assessed. It also gives instructions concerning the presentation and content of the application dossier. |
(3) |
The detailed scientific and technical requirements of Annex I to Directive 2001/82/EC need to be adapted to take account of scientific and technical progress and in particular of a set of new requirements resulting from recent legislation. The presentation and content of the marketing authorisation application dossier should be improved in order to facilitate the assessment and the better use of certain parts of the dossier which are common to several veterinary medicinal products. |
(4) |
In order to simplify current procedures for the assessment of veterinary vaccines, both for the granting of a first marketing authorisation and for the subsequent changes to it due to modifications to the manufacturing process and testing of individual antigens involved in combined vaccines, a new system based on the concept of a master file (Vaccine Antigen Master File, VAMF) should be introduced for vaccines which involve several antigens. |
(5) |
To permit authorisation of vaccines against antigenically variable viruses in a way that ensures that the most effective measures can be taken swiftly by the Community against the incursion or spread of epizootic diseases, the concept of multi-strain dossier should be introduced. This will at the same time ensure that marketing authorisations are granted on the basis of objective scientific criteria of quality, safety and efficacy. |
(6) |
The measures provided for in this Directive are in accordance with the opinion of the Standing Committee for Veterinary Medicinal Products, |
HAS ADOPTED THIS DIRECTIVE:
Article 1
Annex I to Directive 2001/82/EC is replaced by the text set out in the Annex to this Directive.
Article 2
Member States shall bring into force the laws, regulations and administrative provisions necessary to comply with this Directive by 6 September 2009 at the latest. They shall forthwith communicate to the Commission the text of those provisions and a correlation table between those provisions and this Directive.
When Member States adopt those provisions, they shall contain a reference to this Directive or be accompanied by such a reference on the occasion of their official publication. Member States shall determine how such reference is to be made.
Article 3
This Directive shall enter into force on the 20th day following its publication in the Official Journal of the European Union.
Article 4
This Directive is addressed to the Member States.
Done at Brussels, 10 February...
More
This text has been adopted from EUR-Lex.
This dossier is compiled each night drawing from aforementioned sources through automated processes. We have invested a great deal in optimising the programming underlying these processes. However, we cannot guarantee the sources we draw our information from nor the resulting dossier are without fault.
This page is also available in a full version containing the legal context, de Europese rechtsgrond, other dossiers related to the dossier at hand and the related cases of the European Court of Justice.
The full version is available for registered users of the EU Monitor by ANP and PDC Informatie Architectuur.
The EU Monitor enables its users to keep track of the European process of lawmaking, focusing on the relevant dossiers. It automatically signals developments in your chosen topics of interest. Apologies to unregistered users, we can no longer add new users.This service will discontinue in the near future.